A fast growing genetically engineered salmon is a good bet for approval by the Food and Drug Administration. It would be the first genetically modified animal sold as food. Dubbed “Frankenfish” by opponents, the new version of Atlantic salmon was developed by AquaBounty Technologies. It grows almost twice as fast as farm-raised salmon, thanks to one growth hormone gene from a chinook salmon and another from an eel, the ocean pout. The application has been pending before the agency for well over 10 years.
A congressional effort to ban the fish will fail, although it’s a fair bet that lawmakers will give the FDA the authority to require a label identifying the produce as genetically modified. “Approval of genetically modified salmon, the first such hybrid to be considered for human consumption, is unprecedented, risky and a threat to the survival of wild species,” says Sen. Mark Begich, D-Alaska, whose state has a thriving salmon industry.
Also likely to be on the table: Broadening the mission of regulators to ensure they consider environmental risks before granting future approvals -- not just whether the food is safe and whether animals are harmed by the genetic manipulation.
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
A push to add greater public input to the approval process is also a good bet. The current procedure is similar to that for new drugs, with limited public participation. “The current process is confidential. It’s not transparent or participatory,” says Gregory Jaffe of the Center for Science in the Public Interest.
Next up: The Enviropig -- a porker genetically altered to make the manure it produces less polluting, with phosphorus levels 30% to 65% lower than normal. It’s being developed by scientists at the University of Guelph in Canada. Also in the works from Hematech Inc. are cattle that are not susceptible to mad cow disease. The animals lack a protein that mutates, so they don’t get the disease and can’t pass it on.
-
AI Goes To SchoolThe Kiplinger Letter Artificial intelligence is rapidly heading to K-12 classrooms nationwide. Expect tech companies to cash in on the fast-emerging trend.
-
Where to Invest in an Uncertain MarketIn an uncertain market, you can still pocket juicy payouts ranging from 4% to 14%, depending on risk.
-
The New AI Agents Will Tackle Your To-Do ListThe Kiplinger Letter Autonomous AI agents “see” your computer screen, then complete a task, from buying a concert ticket to organizing email. This opens up a world of possibilities.
-
AI’s Medical RevolutionThe Kiplinger Letter Medicine is a field ripe for finding both exciting and practical uses for AI. The tech is already being used by doctors and researchers.
-
The Economic Impact of the US-China Trade WarThe Letter The US-China trade war will impact US consumers and business. The decoupling process could be messy.
-
AI Heads to WashingtonThe Kiplinger Letter There’s big opportunity for AI tools that analyze MRIs and other medical images. But also big challenges that clinicians and companies will have to overcome.
-
The AI Doctor Coming to Read Your Test ResultsThe Kiplinger Letter There’s big opportunity for AI tools that analyze CAT scans, MRIs and other medical images. But there are also big challenges that human clinicians and tech companies will have to overcome.
-
The New Space Age Takes OffThe Kiplinger Letter From fast broadband to SOS texting, space has never been more embedded in peoples’ lives. The future is even more exciting for rockets, satellites and emerging space tech.
-
Rising AI Demand Stokes Undersea InvestmentsThe Kiplinger Letter As demand soars for AI, there’s a need to transport huge amounts of data across oceans. Tech giants have big plans for new submarine cables, including the longest ever.
-
What DOGE is Doing NowThe Kiplinger Letter As Musk's DOGE pursues its ambitious agenda, uncertainty and legal challenges are mounting — causing frustration for Trump.
